(CRGX) CARGO Therapeutics Common - Ratings and Ratios
Cancer, Therapies, Chimeric, Antigen, CAR, T-cell
CRGX EPS (Earnings per Share)
CRGX Revenue
Description: CRGX CARGO Therapeutics Common
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of chimeric antigen receptor (CAR) T-cell therapies to combat cancer. By focusing on innovative treatments for B-cell malignancies, the company is at the forefront of addressing significant unmet medical needs. Its lead product candidate, CRG-022, is an autologous CD22 CAR T-cell therapy designed to overcome resistance to existing treatments by targeting the CD22 antigen. Additionally, the company is advancing CRG-023, a tri-specific CAR T product that targets three distinct B-cell antigens on tumor cells, potentially enhancing treatment efficacy.
The companys approach is built on the premise that CAR T-cell therapies can revolutionize cancer treatment by providing more targeted and potentially curative options. With CRG-022 and CRG-023, CARGO Therapeutics aims to improve outcomes for patients with B-cell malignancies who have limited treatment options. The development of these therapies is grounded in a deep understanding of cancer biology and immunotherapy, positioning the company for potential success in a rapidly evolving field.
Analyzing the
Given the current market capitalization of $210.46M and the absence of a price-to-earnings ratio due to negative earnings, investors are likely speculating on the companys future potential rather than current profitability. The Return on Equity (RoE) of -42.66 indicates significant investment in research and development, aligning with the companys clinical-stage status and growth strategy.
Forecasting the future performance of CRGX involves considering both its technical and fundamental aspects. If CRG-022 and CRG-023 demonstrate positive clinical trial results, this could significantly boost the stock price. Conversely, negative trial outcomes or increased competition could negatively impact the stock. Technically, a break above the SMA20 at $4.40 could signal a short-term bullish trend, while a sustained move above $12.74 (SMA200) would be a strong indicator of long-term growth. Investors should closely monitor clinical trial updates and industry trends to gauge the companys potential for success.
Additional Sources for CRGX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
CRGX Stock Overview
Market Cap in USD | 190m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2023-11-10 |
CRGX Stock Ratings
Growth Rating | -51.1 |
Fundamental | -30.0 |
Dividend Rating | 0.0 |
Rel. Strength | -68.5 |
Analysts | 2.83 of 5 |
Fair Price Momentum | 2.96 USD |
Fair Price DCF | - |
CRGX Dividends
Currently no dividends paidCRGX Growth Ratios
Growth Correlation 3m | 6.5% |
Growth Correlation 12m | -74.5% |
Growth Correlation 5y | -71.5% |
CAGR 5y | -51.29% |
CAGR/Max DD 5y | -0.57 |
Sharpe Ratio 12m | 0.58 |
Alpha | -90.20 |
Beta | 1.641 |
Volatility | 65.64% |
Current Volume | 24778.9k |
Average Volume 20d | 371.2k |
Stop Loss | 4.4 (-3.9%) |
As of July 09, 2025, the stock is trading at USD 4.58 with a total of 24,778,852 shares traded.
Over the past week, the price has changed by +9.31%, over one month by -1.29%, over three months by +18.65% and over the past year by -71.38%.
Probably not. Based on ValueRay´s Fundamental Analyses, CARGO Therapeutics Common (NASDAQ:CRGX) is currently (July 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -30.00 and therefor a somewhat negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRGX is around 2.96 USD . This means that CRGX is currently overvalued and has a potential downside of -35.37%.
CARGO Therapeutics Common has received a consensus analysts rating of 2.83. Therefor, it is recommend to hold CRGX.
- Strong Buy: 0
- Buy: 0
- Hold: 5
- Sell: 1
- Strong Sell: 0
According to our own proprietary Forecast Model, CRGX CARGO Therapeutics Common will be worth about 3.6 in July 2026. The stock is currently trading at 4.58. This means that the stock has a potential downside of -22.49%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 11.2 | 144.1% |
Analysts Target Price | 11.2 | 144.1% |
ValueRay Target Price | 3.6 | -22.5% |